Breaks Categories: News

ThursdayJul 06, 2017 11:46 am

NetworkNewsBreaks – Moleculin Biotech, Inc. (NASDAQ: MBRX) Names Lead European Principal Investigator in Anticipated Annamycin Clinical Trial

Shares of Moleculin Biotech (NASDAQ: MBRX) are up 11% after the company named Dr. Lidia Gil of Poznan University of Medical Sciences in Poznan, Poland, as the lead European Principal Investigator for the upcoming planned phase I/II clinical trial of Annamycin for the treatment of relapsed or refractory acute myeloid leukemia (AML). The trial will commence if the company’s IND is permitted. "Dr. Gill is a dedicated investigator in AML and will bring significant expertise in the area as well as her potential to accelerate enrollment and the completion of our trial," Moleculin's chief medical officer, Dr. Robert Shepard, stated…

Continue Reading

ThursdayJul 06, 2017 10:21 am

NetworkNewsBreaks – ABcann Global Corporation (TSXV: ABCN) Included in the Horizons Medical Marijuana Life Sciences ETF

ABcann Global Corporation (TSXV: ABCN) yesterday announced its inclusion in the Horizons Medical Marijuana Life Sciences ETF (TSX: HMMJ). The ETF is a first-of-its-kind index offering investors direct exposure to a basket of North American life sciences companies with significant business activities in the medical marijuana sector. “The Horizons ETF represents a new type of investment, a fund that tracks an industry in which there is considerable interest but which had no prior investment vehicle through which investors could gain broad exposure,” Aaron Keay, CEO of ABcann, stated in the news release. “Our inclusion in the ETF represents an important…

Continue Reading

WednesdayJul 05, 2017 12:10 pm

NetworkNewsBreaks – Soleno Therapeutics, Inc. (NASDAQ: SLNO) Surges on Positive Guidance from FDA for DCCR in Prader-Willi Syndrome

Soleno Therapeutics (NASDAQ: SLNO) shares are up 11% on news that the company has received the minutes from a scientific advice meeting from the U.S. Food and Drug Administration (FDA) regarding Diazoxide Choline Controlled-Release (DCCR) for the treatment of Prader-Willi syndrome (PWS). The company previously submitted data from a phase II study of DCCR in PWS patients, as well as data from other studies conducted with DCCR. The company agreed with the FDA’s suggestion that the duration of the study should be shorter and that DCCR safety information could be obtained in a long-term, safety extension study. Soleno said it…

Continue Reading

WednesdayJul 05, 2017 12:07 pm

NetworkNewsBreaks – DryShips, Inc. (NASDAQ: DRYS) Takes Delivery of Its Second Modern Newcastlemax Vessel; Shares Higher

Shares of DryShips (NASDAQ: DRYS) are up 12% mid-day after the company earlier said it has taken delivery of its previously announced 205,123 DWT Newcastlemax drybulk vessel. The vessel, which is the second for the owner of ocean-going cargo vessels, was built in 2013. Per a previous agreement, the vessel will be employed under a time charter contract with a major coal and steel trader for a gross rate linked to the new Baltic Capesize Index (BCI5TC) plus 20%. To view the full press release, visit: http://nnw.fm/1v0SD About DryShips Inc. The company is a diversified owner of ocean going cargo…

Continue Reading

FridayJun 30, 2017 2:12 pm

NetworkNewsBreaks – Player’s Network, Inc. (PNTV) Announces Availability of Green Leaf Farms Rosin Products at Las Vegas Dispensary

Player’s Network, Inc. (OTCQB: PNTV) today announced the availability of its Green Leaf Farms rosin products at the Pisos Dispensary, located just a few miles from the Las Vegas Strip. “This day has been a long time coming. It marks both the end of prohibition and the true beginning of mass distribution for Green Leaf Farms products,” Mark Bradley, CEO of Player’s Network, stated in the news release. “Our products are now available at the Pisos Dispensary in Las Vegas, as well as in top notch dispensaries in Henderson. We are aggressively moving on the opportunities provided by this growing…

Continue Reading

FridayJun 30, 2017 1:19 pm

NetworkNewsBreaks – Aeterna Zentaris, Inc. (NASDAQ: AEZS) Resubmits NDA for Macrilen™ for the Evaluation of AGHD in Adults

Aeterna Zentaris (NASDAQ: AEZS) shares are higher after the company this morning said that is has resubmitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of Macrilen™ for the evaluation of growth hormone deficiency in adults (AGHD). The resubmission comes ahead of the company’s previously announced schedule, and the company anticipates an FDA review period of six months. “We anticipate successful FDA approval and, as a result, we continue to build our commercial organization and infrastructure in preparation for the earliest possible launch of Macrilen™. Our focus is to be prepared to launch…

Continue Reading

FridayJun 30, 2017 11:46 am

NetworkNewsBreaks – ABcann Global Corporation (TSXV: ABCN) Announces Appointment of Dr. Michael Shannon as Chief Medical Consultant

On Thursday, ABcann Global Corporation (TSXV: ABCN) announced that it has retained the services of Dr. Michael Shannon as its chief medical consultant. Shannon brings decades of health care experience to the ABcann team, including time in both the private and public sectors. Among Shannon’s career highlights, in 1996, he assumed responsibilities within Health Canada for re-organizing the Canadian blood system and the development of a new corporate entity dedicated exclusively to the management of blood services in Canada. In 2000, he entered the private sector, simultaneously directing a phase III clinical trial in Canada, the United States and Great…

Continue Reading

FridayJun 30, 2017 11:01 am

NetworkNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Featured in Benzinga Article Evaluating Potential of Cannabinoids in Treating Alzheimer’s

On Thursday, India Globalization Capital, Inc. (NYSE MKT: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, was featured in an article on Benzinga titled ‘Marijuana Could Help Treat Alzheimer's: Here's How It Would Work’. The article notes that soon after discovering the pathway by which low-dose THC binds to amyloid beta plaques and prevents them from aggregating on neurons, the University of South Florida filed a patent for that mechanism. Notably, IGC announced on June 12 that it had acquired exclusive rights to this patent, titled ‘THC as a Potential Therapeutic Agent for Alzheimer’s Disease’,…

Continue Reading

ThursdayJun 29, 2017 3:28 pm

NetworkNewsBreaks – SinglePoint, Inc. (SING) Enters High-Volume Manufacturing Agreement with Premier Biomedical (BIEI)

Premier Biomedical, Inc. (OTCQB: BIEI), a research-based company focused on the discovery and development of medical treatments for a wide range of diseases, this morning announced that it has reached an agreement with specialized holding company SinglePoint, Inc. (OTC: SING) to manufacture Premier’s new-design CBD Hemp Oil Patch in high volume. “We have been working very hard on making acquisitions and inside sales to boost revenues,” Greg Lambrecht, CEO of SinglePoint, stated in the news release. “This new business will contribute significantly to our revenue goals.” Per the update, Premier’s CBD Hemp Oil Skin Patch is expected to be the…

Continue Reading

ThursdayJun 29, 2017 9:28 am

NetworkNewsBreaks – Patriot One Technologies (TSX.V: PAT) (OTCQB: PTOTF) Enters Reseller Agreement with New Zealand’s Aotea Security

Patriot One Technologies, Inc. (TSX.V: PAT) (OTCQB: PTOTF), developer of the award-winning PATSCAN CMR™ concealed weapons detection system, this morning announced its entry into a reseller agreement with Aotea Security (NZ) Ltd., an accredited national systems integration company based in Dunedin, New Zealand. “This agreement ushers in a whole new region for our sales efforts and we are delighted that our first partner in the area has the infrastructure and experience to service the entire country of New Zealand,” Martin Cronin, CEO of Patriot One, stated in the news release. “We are moving quickly to finalize matters and look forward…

Continue Reading